Spark Biomedical Deepens Behavioral Health & Neurostimulation Expertise with Two Key Hires

Spark Biomedical Deepens Behavioral Health & Neurostimulation Expertise with Two Key Hires

Read MorePress Releases

Dallas, Texas, April 22, 2021 — Spark Biomedical, Inc. is pleased to announce the strategic hire of two new Vice President level team members, Stephen Guidry as VP of Sales and Stephanie Washburn as VP of Clinical and Medical Affairs.

Spark CEO Daniel Powell stated, “We are thrilled to see the team continue to grow with such great talent. Both new hires represent our ongoing commitment to the behavioral health space as well as our dedication to continuing to advance the science of neurostimulation in withdrawal and addiction.”
Stephen Guidry

Mr. Guidry, Spark’s new VP of Sales, is a natural addition to round out the Spark sales leadership team, bringing to bear 26 years of Pharmaceutical and Biotech leadership experience and a career focused on Central Nervous System disorders — the last 12 of which were explicitly dedicated to Substance Abuse. Most recently, Mr. Guidry was a Sr. Regional Sales Director for Alkermes, responsible for VIVITROL in the Central Region and led the Key Account Management (KAM) team at Alkermes from 2011-2017, primarily focused on National Treatment Systems and Criminal Justice.

Guidry noted, “I’m honored and humbled to begin my journey at Spark Biomedical. Having the ability to offer patients and providers an alternative treatment for withdrawal management is long overdue. The Sparrow Therapy System is a much-needed treatment modality for patients suffering from Opiate Use Disorder. These patients are truly counting on us to deliver. I can’t wait to get started!”

“Sparrow was conceived to help those in need of opioid reduction or elimination overcome their fear of withdrawal, heal from the damaging effects of long-term use, and achieve a better quality of life,” said SVP of Sales, Victor Vozzo. “This vision cannot be realized in the absence of successful partnerships with innovative thought leaders who share this goal. Stephen brings a depth of knowledge and experience that accelerates our efforts so patients in need can benefit from our game-changing therapy as a soon as possible. I’m thrilled to have him on our team.”

Stephaine Washburn, Ph.D.

Stephanie Washburn, Ph.D., Spark’s new VP of Clinical and Medical Affairs, spent a significant portion of her career in clinical and medical affairs in the neurostimulation space, specifically with 10+ years’ experience at St. Jude Medical Neuromodulation. Previously, Dr. Washburn held the Medical Science Liaison role at ElectroCore, responsible for Key Opinion Leader identification and engagement. Prior to that, Dr. Washburn was an independent consultant accountable for helping start-ups in the medical device space design and execute clinical trials, most of which were pivotal trials for product commercialization.

“With close to 15 years of experience in clinical and medical affairs in the neurostimulation sector and my most recent experience with vagal nerve stimulation, I felt my background was a natural fit for Spark, particularly in a company so dedicated to advancing the science around opioid withdrawal and addiction treatment,” said Dr. Washburn.
“At Spark, our fundamental goal is to use world-class science to help patients in need, and I am excited to welcome top-tier scientific professionals to our Spark team to advance that mission,” said Navid Khodaparast, Ph.D., Spark’s Chief Science Officer. “With the addition of Dr. Washburn’s expertise in neuropathic pain, I am confident we are set up for success as we continue to develop our clinical pipeline.”

About Spark Biomedical

Spark Biomedical, Inc. is a Texas-based medical device company and developer of the first drug-free, needle-free, wearable solution for opioid withdrawal relief backed by evidence from a double-blind, randomized controlled clinical trial targeting patients with opioid use disorder.

The Sparrow Therapy System uses Transcutaneous Auricular Neurostimulation (tAN) to treat withdrawal symptoms by stimulating nerves on and around the ear. The wearable earpiece is designed to be worn up to 24 hours a day throughout opioid reduction or as prescribed to aid in the reduction of withdrawal symptoms.

The company’s vision to ignite a brighter future for those struggling with opioid addiction and dependence is fueled by its unique blend of scientific expertise, technical innovation, and deep medical device industry experience. For more information, schedule a consultation at